ITOS
iTeos Therapeutics, Inc.
9.83
USD
This page is just a preview of the data found in TrendSpider’s full version
iTeos Therapeutics, Inc. stock is up 2.82% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 December’s closed higher than November. In the last 5 Unusual Options Trades, there were 5 PUTs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 11 Oct 17:49 | 19 Jan, 2024 | 10.00 | 3059 | ||
| 12 Oct 14:15 | 19 Jan, 2024 | 10.00 | 6215 | ||
| 12 Oct 14:15 | 19 Jan, 2024 | 10.00 | 6215 | ||
| 12 Oct 14:15 | 19 Jan, 2024 | 10.00 | 6215 | ||
| 12 Oct 14:15 | 19 Jan, 2024 | 10.00 | 6215 |
Iteos Therapeutics, Inc. engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials. EOS-448 is an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains.
